Patent US2603689A successfully refreshed from Google Patents.
Patent US4983580A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4983580A Expired / Lapsed US ⏱️ 0.0 years remaining

Methods and materials for use in corneal wound healing

Assignee: Allergan Inc
•
Filing: 1990-03-07
•
Granted: 1991-01-08
•
Expires: 2010-03-07
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Improvement in healing of wounds of the corneal stroma is obtained by placing into the wounds a corneal mortar composition comprising an extracellular matrix material and an ophthalmologically compatible carrier material, the composition having a sufficiently high viscosity to retain it within the wound under wound-healing conditions.

Inventors

  • 👤 David R. Gibson

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 19:20
CPC Classifications
A; A61; A61L; A61L26/00; A61L26/0009; A61F; A61F9/00; A61F9/007; A61F2/00; A61F2/02; A61F2/14; A61F2/142; A61F2/147; A61K; A61K9/00; A61K9/0012; A61K9/0048; A61K9/0051; A61L26/0023; A61L26/0061; A61L26/0066; A61F13/00; A61F13/15; A61F13/84; A61F13/8405; A61F2013/00089; A61F2013/00217; A61F2013/00221; A61L2300/00; A61L2300/40; A61L2300/412; A61L2300/414

Claims Analysis

Total Claims: 16
Claim 1
Independent Claim 82 words
A method for enhancing corneal healing following keratorefractive surgery in which incisions are made into the corneal stroma, the method comprising placing into the incisions a corneal mortar composition comprising at least one extracellular matrix material selected from the group consisting of fibronectin, collagen, vitronectin, elastin, laminin, actin, fibrinogen, chondroitin sulfate, heparin, keratin sulfate and hyaluronic acid and an ophthalmologically compatible carrier material, said composition having a sufficiently high viscosity to retain the extracellular matrix material within the incision under incision-healing conditions.
Claim 2
Independent Claim 82 words
A method for enhancing corneal healing following keratorefractive surgery in which incisions are made into the corneal stroma, the method comprising placing into the incisions a corneal mortar composition comprising at least one extracellular matrix material selected from the group consisting of fibronectin, collagen, vitronectin, elastin, laminin, actin, fibrinogen, chondroitin sulfate, heparin, keratin sulfate and hyaluronic acid and an ophthalmologically compatible carrier material, said composition having a sufficiently high viscosity to retain the extracellular matrix material within the incision under incision-healing conditions.
Claim 3
Dependent Claim 26 words
A method as claimed in claim 1, wherein the corneal mortar composition comprises an extracellular matrix material, a growth factor and an ophthalmologically compatible carrier material.
Claim 4
Dependent Claim 15 words
A method as claimed in claim 2, wherein the growth factor is epidermal growth factor.
Claim 5
Dependent Claim 20 words
A method as claimed in claim 1, wherein the extracellular matrix material is selected from fibronectin, chondroitin sulfate, and collagen.
Claim 6
Dependent Claim 20 words
A method as claimed in claim 1, wherein the corneal mortar composition comprises fibronectin and an ophthalmologically compatible carrier material.
Claim 7
Dependent Claim 22 words
A method as claimed in claim 1, wherein the corneal mortar composition contains from about 0.5% to about 90% by weight fibronectin.
Claim 8
Dependent Claim 22 words
A method as claimed in claim 1, wherein the corneal mortar composition comprises fibronectin, chondroitin sulfate and an ophthalmologically compatible carrier material.
Claim 9
Dependent Claim 23 words
A method as claimed in claim 1, wherein the corneal mortar composition comprises fibronectin, a growth factor and an ophthalmologically compatible carrier material.
Claim 10
Dependent Claim 23 words
A method as claimed in claim 1, wherein the corneal mortar composition comprises fibronectin, chondroitin sulfate, collagen and an ophthalmologically compatible carrier material.
Claim 11
Dependent Claim 25 words
A method as claimed in claim 1, wherein the corneal mortar composition comprises fibronectin, chondroitin sulfate, a growth factor and an ophthalmologically compatible carrier material.
Claim 12
Dependent Claim 40 words
A method as claimed in claim 5, wherein the corneal mortar composition comprises from about 2% to about 40% fibronectin and from about 98% to about 60% of an ophthalmologically compatible carrier material, based on total weight of the composition.
Claim 13
Dependent Claim 48 words
A method as claimed in claim 7, wherein the corneal mortar composition comprises from about 0.5% to about 40% fibronectin, from about 0.5% to about 75% chondroitin sulfate and from about 25% to about 99% of an ophthalmologically compatible carrier material, based on total weight of the composition.
Claim 14
Dependent Claim 52 words
A method as claimed in claim 8, wherein the corneal mortar composition comprises from about 2% to about 40% fibronectin, from about 60% to about 98% of an ophthalmologically compatible carrier material, based on total weight of the composition, and from about 0.01 μg/ml to about 100 μg/ml of a growth factor.
Claim 15
Dependent Claim 48 words
A method as claimed in claim 9, wherein the corneal mortar composition comprises from about 0.5% to about 40% fibronectin, from about 0.5% to about 75% chondroitin sulfate, from about 0.5% to about 50% collagen and from about 35% to about 98.5% of an ophthalmologically compatible carrier material.
Claim 16
Dependent Claim 58 words
A method as claimed in claim 10, wherein the corneal mortar composition comprises from about 0.5% to about 40% fibronectin, from about 0.5% to about 75% chondroitin sulfate, from about 25% to about 99% phosphate buffered saline solution, based on total weight of the composition, and from about 0.01 μg/ml to about 100 μg/ml of a growth factor.

References Cited (Backward Citations)

US4486416A Cited
US4458678A Cited
EP0190018A2 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1994-01-07 1994-07-09 1995-01-08 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1998-01-07 1998-07-09 1999-01-08 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2002-01-07 2002-07-09 2003-01-08 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag